DIPG (diffuse intrinsic pontine glioma) is a rare, fast-growing brain tumor that forms in a part of the brainstem called the pons. It primarily affects children, typically between the ages of 5 and 9, and is one of the most difficult cancers in pediatric medicine. The median survival after diagnosis is about 11 months, and fewer than 3% of children survive five years even with treatment.
Where DIPG Grows and Why That Matters
The pons is a small section of the brainstem that sits between the upper brain and the spinal cord. It acts as a relay station for signals controlling breathing, swallowing, eye movement, facial expressions, balance, and heart rate. The tumor doesn’t form a solid mass that can be separated from healthy tissue. Instead, it weaves diffusely through the pons, tangling itself into the nerve fibers that control these basic functions.
This is why surgery is essentially off the table. The tumor cells are so intertwined with critical neural pathways that attempting to remove them would almost certainly cause severe, life-threatening neurological damage. Unlike many other brain tumors where a surgeon can cut around the growth, DIPG leaves no clean margin to work with.
The Genetic Mutation Behind Most Cases
Between 80% and 90% of DIPG tumors carry a specific genetic error known as the H3K27M mutation. This mutation affects histone proteins, which act like spools that DNA wraps around. Normally, chemical tags on these spools help keep certain genes switched off. The H3K27M mutation disrupts that tagging system, loosening the DNA structure and allowing genes involved in rapid cell growth and stem cell behavior to switch on when they shouldn’t be.
The result is a tumor with stem cell-like properties that grows aggressively and resists radiation. Because of this mutation’s central role, the World Health Organization reclassified these tumors in 2021 under a broader category called “diffuse midline glioma, H3 K27-altered.” DIPG remains widely used as a clinical term, but the updated name reflects the underlying biology more precisely.
How Symptoms Appear
DIPG symptoms tend to come on quickly, often over just a few weeks. Because the pons controls so many basic functions, the signs can be varied and alarming. Common early symptoms include:
- Double vision or an eye turning inward
- Drooping on one side of the face
- Difficulty with balance and walking
- Problems talking, chewing, or swallowing
- Weakness in the arms or legs
- Morning headaches that improve after vomiting
- Nausea and vomiting
- Behavioral changes or new difficulty with schoolwork
Parents often notice a combination of these signs developing over days to weeks rather than months. The rapid onset is one of the features that distinguishes DIPG from slower-growing brain tumors.
How DIPG Is Diagnosed
Diagnosis relies heavily on MRI imaging. Radiologists look for a tumor that arises from the pons, spreads diffusely through the tissue, and involves at least 50% of the pons on cross-sectional imaging. They also evaluate the tumor’s borders, signal characteristics, whether it has spread beyond the pons, and whether there are signs of bleeding or tissue death within the mass.
In many cases, these imaging features are distinctive enough that a biopsy isn’t required to make the diagnosis. Given the risks of inserting a needle into the brainstem, biopsy is reserved for situations where imaging is ambiguous or when molecular information is needed to guide enrollment in a clinical trial. When a biopsy is performed, it can confirm the H3K27M mutation and provide additional detail about the tumor’s biology.
Treatment Options and Their Limits
Radiation therapy is the standard treatment. The typical course delivers radiation to the tumor over about six weeks. Roughly 70% to 80% of children experience temporary improvement in their neurological symptoms after radiation. They may walk better, swallow more easily, and regain some facial movement. For many families, this period of improvement is meaningful, providing weeks or months of better quality of life.
The relief is temporary. In most children, symptoms return as the tumor begins growing again, typically around six months after radiation ends. Radiation extends overall survival by several months compared to no treatment, but it does not cure the disease. Data from a large European registry found that children who received radiation along with chemotherapy had a 3% five-year survival rate. Those who received radiation alone, or no treatment at all, had a 0% five-year survival rate.
Chemotherapy has not shown meaningful benefit for DIPG when added to radiation. Decades of clinical trials testing various drug combinations have failed to improve outcomes significantly, largely because the blood-brain barrier limits drug delivery to the pons and the tumor’s biology makes it inherently resistant to many therapies.
Experimental Approaches
One of the more closely watched experimental treatments is ONC201, a small-molecule drug that can cross the blood-brain barrier and has shown activity specifically against H3K27M-mutant tumors. Multi-center clinical trials have been testing ONC201 both as a standalone treatment and in combination with radiation, with early results generating cautious interest. The drug is given orally, which is notable because most brain tumor treatments require infusion or injection.
Researchers are also exploring immunotherapy approaches, including engineered immune cells designed to recognize and attack tumor cells carrying the H3K27M mutation. These strategies are still in early-stage trials, and it remains unclear whether they will translate into survival improvements. The tumor’s location deep in the brainstem and its ability to suppress local immune responses present significant hurdles.
What the Diagnosis Means for Families
DIPG accounts for roughly 200 to 400 new diagnoses per year in the United States. Because it strikes children during early school years, families are often navigating the diagnosis alongside school, siblings, and the routines of daily life. The speed of symptom onset means many families go from a first doctor’s visit to a confirmed diagnosis within days.
After radiation, there is often a window where a child feels and functions significantly better. Families sometimes describe this as a “honeymoon period.” Planning around this window, whether for experiences, time together, or simply a return to normalcy, becomes an important part of how families cope. As the tumor progresses, symptoms gradually worsen, and care shifts toward comfort and quality of life. The trajectory varies from child to child, but the median survival of 11.2 months from diagnosis reflects how aggressive this tumor is.